Leo And La Jolla Drop Lupus Drug Plans
Leo Pharmaceutical Products of Denmark has terminated its agreement with La Jolla Pharmaceuticals over La Jolla's experimental drug for lupus erythematosus, LJP 394. Leo had agreed to develop and market the drug in Europe and the Middle East.
After reporting positive Phase II data with the drug in the first quarter of this year (Marketletter March 4), Leo and La Jolla reviewed their strategy for taking the drug through further clinical development, and could not reach an agreement on how best to proceed, according to La Jolla.
La Jolla retains $3 million in funding which was previously paid by Leo, and no further financial commitments are forthcoming. La Jolla says it will begin a Phase IIb study in the second-half of 1996, but has not yet made a decision on whether to retain European and Middle East marketing rights or seek another strategic partner for these territories.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze